The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Proactively managing atrial fibrillation is crucial for patients and healthcare providers, often necessitating the use of drugs due to the condition's propensity for severe consequences ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Doylestown Health is broadening its treatment options for atrial fibrillation patients with a revolutionary system that ...

Atrial fibrillation (AF) is a common heart condition that affects about one in three people at some point in their lives. It ...

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...

The Circular Ring 2 features an AFib detection system that should greatly help the device find its space in the smart ring ...